Genedata and Axxam Announce High Throughput Screening Data Analysis Collaboration
News Jul 07, 2008
According to Genedata, Screener’s high-quality, high-performance modular system flexibly analyzes, integrates and manages all assay data and then combines it with chemical, pharmacological and in vivo information to support Axxam scientists in prioritizing compounds and identifying quality lead structures with the highest confidence.
Screener`s open and scalable architecture integrates with existing infrastructures, which allows it to be tailored to specific discovery processes, maximizing value, the company said.
Dr. Stefan Lohmer, CEO of Axxam, said, ”Establishing flexible and efficient working practices to ensure client satisfaction is our top priority as a reputable service provider. Genedata`s consistently high performance and data quality along with their expertise and profound scientific knowledge enable us to meet that goal on a daily basis, with rigorous quality control covering every detail, as well as keeping to deadlines and budget terms. Thus, our focus extends beyond the actual license agreement with Genedata, towards a comprehensive, long-term partnership in high throughput screening.”
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019